Stelios Papadopoulos's Insider Trades & SAST Disclosures
Stelios Papadopoulos's most recent trade in Exelixis Inc was a trade of 18,838 Common Stock done . Disclosure was reported to the exchange on May 31, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Stelios Papadopoulos.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Exelixis Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 18,838 | 1,279,416 (0%) | 0% | 0 | Common Stock | |
| Regulus Therapeutics Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2024 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Exelixis Inc | Stelios Papadopoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.57 per share. | 20 May 2024 | 11,686 | 1,272,015 (0%) | 0% | 19.6 | 228,695 | Common Stock |
| Exelixis Inc | Stelios Papadopoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 11,686 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Stelios Papadopoulos | Director | Sale of securities on an exchange or to another person at price $ 21.00 per share. | 20 May 2024 | 11,437 | 1,260,578 (0%) | 0% | 21 | 240,177 | Common Stock |
| Regulus Therapeutics Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 1.60 per share. | 14 Mar 2024 | 250,000 | 978,388 (4%) | 1% | 1.6 | 400,000 | Common Stock |
| Regulus Therapeutics Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 0.90 per share. | 13 Apr 2023 | 222,198 | 728,388 (3%) | 1% | 0.9 | 200,000 | Common Stock |
| Biogen Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 2,255 | 10,095 (0%) | 0% | 0 | Common Stock | |
| Regulus Therapeutics Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Exelixis Inc | Stelios Papadopoulos | Director | Sale of securities on an exchange or to another person at price $ 19.56 per share. | 22 Feb 2022 | 84,515 | 1,220,036 (0%) | 0% | 19.6 | 1,653,113 | Common Stock |
| Regulus Therapeutics Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 0.36 per share. | 30 Nov 2021 | 2,222,222 | 5,061,929 (24%) | 10% | 0.4 | 800,000 | Common Stock |
| Biogen Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 1,275 | 7,840 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Stelios Papadopoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 40,000 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Stelios Papadopoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.38 per share. | 11 May 2021 | 40,000 | 1,293,600 (0%) | 0% | 3.4 | 135,200 | Common Stock |
| Exelixis Inc | Stelios Papadopoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.13 per share. | 11 May 2021 | 40,000 | 1,258,675 (0%) | 0% | 3.1 | 125,200 | Common Stock |
| Exelixis Inc | Stelios Papadopoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.30 per share. | 11 May 2021 | 40,000 | 1,228,897 (0%) | 0% | 6.3 | 252,000 | Common Stock |
| Exelixis Inc | Stelios Papadopoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 40,000 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Stelios Papadopoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 40,000 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Stelios Papadopoulos | Director | Sale of securities on an exchange or to another person at price $ 24.95 per share. | 11 May 2021 | 10,222 | 1,218,675 (0%) | 0% | 25.0 | 255,039 | Common Stock |
| Exelixis Inc | Stelios Papadopoulos | Director | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 11 May 2021 | 5,473 | 1,288,127 (0%) | 0% | 25.0 | 136,880 | Common Stock |
| Exelixis Inc | Stelios Papadopoulos | Director | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 11 May 2021 | 5,075 | 1,253,600 (0%) | 0% | 25 | 126,875 | Common Stock |
| Biogen Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2020 | 1,470 | 6,565 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2020 | 15,538 | 1,188,897 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Stelios Papadopoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2020 | 120,791 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Stelios Papadopoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.82 per share. | 13 May 2020 | 120,791 | 1,173,359 (0%) | 0% | 5.8 | 703,004 | Common Stock |
| Exelixis Inc | Stelios Papadopoulos | Director | Sale of securities on an exchange or to another person at price $ 25.84 per share. | 08 May 2020 | 45,000 | 1,052,568 (0%) | 0% | 25.8 | 1,162,800 | Common Stock |
| Exelixis Inc | Stelios Papadopoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.58 per share. | 08 May 2020 | 30,000 | 1,082,568 (0%) | 0% | 4.6 | 137,400 | Common Stock |
| Exelixis Inc | Stelios Papadopoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2020 | 30,000 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Stelios Papadopoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2020 | 15,000 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Stelios Papadopoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.92 per share. | 08 May 2020 | 15,000 | 1,097,568 (0%) | 0% | 5.9 | 88,800 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges